Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Summary: Interleukin (IL)‐6‐mediated signalling attenuates the anti‐myeloma activity of glucocorticoids (GCs). We therefore sought to evaluate whether CNTO 328, an anti‐IL‐6 monoclonal antibody in clinical development, could enhance the apoptotic activity of dexamethasone (dex) in pre‐clinical models of myeloma. CNTO 328 potently increased the cytotoxicity of dex in IL‐6‐dependent and ‐independent human myeloma cell lines (HMCLs), including a bortezomib‐resistant HMCL. Isobologram analysis revealed that the CNTO 328/dex combination was highly synergistic. Addition of bortezomib to CNTO 328/dex further enhanced the cytotoxicity of the combination. Experiments with pharmacologic inhibitors revealed a role for the p44/42 mitogen‐activated protein kinase pathway in IL‐6‐mediated GC resistance. Although CNTO 328 alone induced minimal cell death, it potentiated dex‐mediated apoptosis, as evidenced by increased activation of caspases‐8, ‐9 and ‐3, Annexin‐V staining and DNA fragmentation. The ability of CNTO 328 to sensitize HMCLs to dex‐mediated apoptosis was preserved in the presence of human bone marrow stromal cells. Importantly, the increased activity of the combination was also seen in plasma cells from patients with GC‐resistant myeloma. Taken together, our data provide a strong rationale for the clinical development of the CNTO 328/dex regimen for patients with myeloma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis
Tai, Y.-T., Fulciniti, M., Hideshima, T., Song, W., Leiba, M., Li, X.-F., Rumizen, M., Burger, P., Morrison, A., Podar, K., et al. (2007) · Blood · doi:10.1182/blood-2007-03-081240 · Cited by 109 · cited 1×
“Similarly, others have shown that a MEK inhibitor in clinical development, AZD6244, sensitized the IL-6-dependent HMCL, INA-6, to dex (Tai et al, 2007).”
BackgroundRetractedInternational uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“…has been shown to enhance the proliferation and survival of myeloma cells, both in suspension and in the presence of bone marrow stromal cells (Kawano et al, 1988; Anderson et al, 1989; Klein et al, 1989; Uchiyama et al, 1993), and to protect them from apoptosis induced by GCs Peter M.…”
BackgroundYang-Yen, H.-F., Chambard, J.-C., Sun, Y.-L., Smeal, T., Schmidt, T. J., Drouin, J., & Karin, M. (1990) · Cell · doi:10.1016/0092-8674(90)90396-v · Cited by 1,553 · cited 2×
“…transcriptional activation 484 ª 2009 Blackwell Publishing Ltd, British Journal of Haematology, 145, 481–490 (Jonat et al, 1990; Schule et al, 1990; Yang-Yen et al, 1990; Touray et al, 1991), we investigated the role of the p44/42 MAPK pathway, a known modulator of AP-1 transcriptional…”
BackgroundLenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450 · cited 2×
“…lenalidomide and the proteasome inhibitor bortezomib, GCs remain an important component of multi-agent chemotherapy for newly-diagnosed and relapsed/refractory multiple myeloma (Jagannath et al, 2005; Rajkumar et al, 2005, 2008b; Harousseau et al, 2006; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233 · cited 2×
“…lenalidomide and the proteasome inhibitor bortezomib, GCs remain an important component of multi-agent chemotherapy for newly-diagnosed and relapsed/refractory multiple myeloma (Jagannath et al, 2005; Rajkumar et al, 2005, 2008b; Harousseau et al, 2006; Dimopoulos et al, 2007; Weber et al, 2007).”
BackgroundPromiscuous Mutations Activate the Noncanonical NF-κB Pathway in Multiple Myeloma
Keats, J. J., Fonseca, R., Chesi, M., Schop, R., Baker, A., Chng, W.-J., Van Wier, S., Tiedemann, R., Shi, C.-X., Sebag, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.07.003 · Cited by 983 · cited 1×
“…intrinsic to myeloma cells have been shown to confer GC resistance in vitro, including activating mutations in N-Ras and K-Ras, TNF receptor-associated factor (TRAF)-3 deletions, as well as over-expression of heat shock protein (HSP)-27 (Rowley et al, 2000; Chauhan et al, 2003; Keats et al, 2007).”
BackgroundCombination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma
Rajkumar, S. V., Hayman, S. R., Lacy, M. Q., Dispenzieri, A., Geyer, S. M., Kabat, B., Zeldenrust, S. R., Kumar, S., Greipp, P. R., Fonseca, R., et al. (2005) · Blood · doi:10.1182/blood-2005-07-2817 · Cited by 648
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma
Hideshima, T., Nakamura, N., Chauhan, D., & Anderson, K. C. (2001) · Oncogene · doi:10.1038/sj.onc.1204833 · Cited by 478 · cited 5×
“The combination of bortezomib and dex has demonstrated additive activity in pre-clinical models of myeloma and has proven to be clinically active in newly-diagnosed and relapsed/ refractory patients (Hideshima et al, 2001b; Jagannath et al, 2005, 2006; Harousseau et al, 2006).”
BackgroundInfluential
Cited by
Interleukin-6 signaling pathway in targeted therapy for cancer
Guo, Y., Xu, F., Lu, T., Duan, Z., & Zhang, Z. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.04.007 · Cited by 686
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M., & Yao, Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 664
Interleukin-6 in bone metastasis and cancer progression
Ara, T., & DeClerck, Y. A. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.02.026 · Cited by 379
Zonder, J. A., Mohrbacher, A. F., Singhal, S., van Rhee, F., Bensinger, W. I., Ding, H., Fry, J., Afar, D. E. H., & Singhal, A. K. (2012) · Blood · doi:10.1182/blood-2011-06-360552 · Cited by 342
Bjorklund, C. C., Baladandayuthapani, V, Lin, H. Y., Jones, R. J., Kuiatse, I., Wang, H., Yang, J., Shah, J. J., Thomas, S. K., Wang, M., et al. (2014) · Leukemia · doi:10.1038/leu.2013.174 · Cited by 131
Self-citation
Metadata
- Authors
- Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2009-04-24
- Volume
- 145
- Issue
- 4
- Pages
- 481-490
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2009140079
- Cited by
- 88
- References
- 10
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death. https://app.cochat.ai/papers/10.1111/j.1365-2141.2009.07647.x
- The paper
- Voorhees, P. M., Chen, Q., Small, G. W., Kuhn, D. J., Hunsucker, S. A., Nemeth, J. A., & Orlowski, R. Z. (2009). Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death. British Journal of Haematology. https://doi.org/10.1111/j.1365-2141.2009.07647.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.